News 2018-10-06
Porton will attend 2018 CPhI WW
We own and operate 4 Process Technology Centers and 2 Manufacturing Sites [including one US FDA, Japan PDMA-approved facilities] across China. Supported by >1,500 customer first-oriented employees [including >500 Process Scientists, Operations, Quality Assurance, EHS and Program Management professionals]. Our sites are operated to global quality and environmental standards under a centralized management system.
Others
More
News 2025-07-31
Porton Participates in Publishing an OPRD Paper, Demonstrating Strength in Drug Synthesis Technology
Metal catalytic and DoE technologies for the optimization of CT1812 synthesis routes

News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.